Mon, Jan 26, 2015, 8:21 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Oncothyreon Inc Message Board

  • prudentvoice prudentvoice Mar 24, 2010 10:42 AM Flag

    Another case of resuming after halt (ASTM)

    Dan_Xia found this one. (ASTM)

    See his earlier post

    Halted by FDA May 22, 2009
    Resumed June 17, 2009

    the trial was halted (see link below):

    http://74.125.93.132/search?q=cache:H_KL...

    and resumed (see link below):

    http://74.125.93.132/search?q=cache:xXgw...


    Notice how the stock price reacted.

    The day BEFORE the rise to $3.68 it was actually moved slightly higher ($3.04) than it was the day of the drop ($2.88). It also finished higher overall than the day before the drop.

    PRICES
    Date Open High Low Close Volume Adj Close*

    18-Jun-09 0.44 0.52 0.43 0.46 1,504,900 3.68
    17-Jun-09 0.39 0.39 0.34 0.38 130,300 3.04
    16-Jun-09 0.35 0.40 0.35 0.38 506,400 3.04
    15-Jun-09 0.37 0.37 0.34 0.35 85,600 2.80
    12-Jun-09 0.35 0.36 0.35 0.35 47,200 2.80
    11-Jun-09 0.37 0.37 0.35 0.35 37,400 2.80
    10-Jun-09 0.35 0.37 0.35 0.35 85,900 2.80
    9-Jun-09 0.37 0.37 0.35 0.35 100,400 2.80
    8-Jun-09 0.37 0.38 0.36 0.36 126,300 2.88
    5-Jun-09 0.38 0.38 0.36 0.36 76,200 2.88
    4-Jun-09 0.37 0.38 0.36 0.37 127,200 2.96
    3-Jun-09 0.36 0.38 0.35 0.37 132,400 2.96
    2-Jun-09 0.36 0.37 0.35 0.35 53,800 2.80
    1-Jun-09 0.34 0.37 0.34 0.36 95,000 2.88
    29-May-09 0.34 0.35 0.33 0.34 98,800 2.72
    28-May-09 0.34 0.35 0.34 0.34 61,900 2.72
    27-May-09 0.35 0.36 0.33 0.35 74,200 2.80
    26-May-09 0.34 0.35 0.33 0.33 133,300 2.64
    22-May-09 0.35 0.37 0.32 0.36 594,900 2.88
    21-May-09 0.36 0.44 0.36 0.42 563,800 3.36


    * Close price adjusted for dividends and splits.
    1 : 8 Stock Split on 2/18/2010

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The good old game is on. Doubled down and ready to ride the tide to fruition.

      No risk, not glory!

      God bless the patients who may have been affected!

    • both times a drop of approx. 17% and then a rise of 30-40% upon reactivation of trial.

      luckily only 1 month delay each time.

      but the cause of the two problems was NOT drug related and was obvious.

      With stimuvax probably not stimuvax related but difficult to find the causative agent thus far I think.

    • I'm seeing different dates. And the PR says they had already determined via 2 investigations that the cause was not due to their drug by the time the trial was halted.

      http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=ASTM.O×tamp=20090202115600

      • 2 Replies to jojox1111
      • Hello jojox1111,

        From the link you sent

        May 22,2009 news piece - on hold

        June 18,2009 news piece - FDA hold lifted

        Look right to you?

      • You looked at the wrong event. the one confused you occurred in Feb.

        The one we are talking occurred in may (see below):

        Aastrom Biosciences, Inc. Announces FDA Lifts Clinical Hold From Heart Study-Reuters
        Thursday, 18 Jun 2009 07:51am EDT
        Reuters reported that Aastrom Biosciences, Inc. said U.S. health regulators removed the clinical hold from the Company's mid-stage trial of a treatment for congestive heart failure. The Company said it would resume patient enrollment at all five initiated clinical sites. The FDA, the clinical site's principal investigator and an independent Data Safety Monitoring Board (DSMB) attributed the patient's death to progression of the disease and determined it was unrelated to the CRC treatment.
        Aastrom Biosciences, Inc. Places Phase II IMPACT-DCM Clinical Trial On Hold Following Report Of Serious Adverse Event

        Friday, 22 May 2009 06:55am EDT
        Aastrom Biosciences, Inc. announced that it has temporarily suspended enrollment and patient treatment in its U.S. Phase II IMPACT-DCM clinical trial following a report that a patient died at home after being released from the hospital following treatment in the trial. The patient's cause of death has not yet been determined and is the subject of a pending investigation at the clinical site. An independent Data Safety Monitoring Board (DSMB) will also assess the circumstances of the event. In accordance with standard operating procedures, the Company has informed the U.S. Food and Drug Administration (FDA) of the following: the death of the patient after being released from the hospital; the initiation of an investigation into the cause of death; and that the Company has voluntarily suspended patient enrollment and treatment in the trial. Subsequently, the FDA placed the trial on temporary clinical hold pending an investigation. Follow-up of patients previously enrolled in the IMPACT-DCM trial will continue in accordance with study protocol.

 
ONTY
1.64+0.11(+7.19%)Jan 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Microsoft Corporation
NASDAQMon, Jan 26, 2015 4:00 PM EST
Texas Instruments Inc.
NASDAQMon, Jan 26, 2015 4:00 PM EST